Find therapies in clinical trials near you – page 2

Study on Early Drug Withdrawal in Children with Juvenile Idiopathic Arthritis Using Secukinumab and Drug Combination for Those in Clinical Remission

Study on Early Drug Withdrawal in Children with Juvenile Idiopathic Arthritis Using Secukinumab and Drug Combination for Those in Clinical Remission

Methotrexate tapering versus usual care in elderly (≥70) patients with rheumatoid arthritis in low disease activity – drug combination study

Methotrexate tapering versus usual care in elderly (≥70) patients with rheumatoid arthritis in low disease activity – drug combination study

Metformin hydrochloride plus drug combination to reduce pain, inflammation and biological aging in patients with knee osteoarthritis

Metformin hydrochloride plus drug combination to reduce pain, inflammation and biological aging in patients with knee osteoarthritis

Study of ustekinumab, adalimumab, and baricitinib for patients with folliculitis decalvans that is difficult to treat

Study of Baricitinib for Treating Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Study of Baricitinib for Treating Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Study on the Safety and Effects of Baricitinib in People with HIV

Study on the Safety and Effects of Baricitinib in People with HIV

Study on Baricitinib for New-Onset Polymyalgia Rheumatica Patients to Reduce Steroid Use

Study on Baricitinib for New-Onset Polymyalgia Rheumatica Patients to Reduce Steroid Use

Study on Baricitinib for Treating New-Onset Juvenile Dermatomyositis in Children

Study on Baricitinib for Treating New-Onset Juvenile Dermatomyositis in Children

Study of Baricitinib in Children Aged 1 to 17 Hospitalized with COVID-19

Study of Baricitinib in Children Aged 1 to 17 Hospitalized with COVID-19

Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis

Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis